Press Releases
March 17, 2025
HepQuant to Present at Key Liver Conferences to Highlight Applications of HepQuant DuO™ – a Quantitative Liver Health Test
Recent clinical data demonstrates how HepQuant DuO test results may be used to inform endoscopy screening decisions, monitor disease progression and evaluate response to resmetirom therapy in patients with compensated advanced chronic liver disease (cACLD). Denver, CO – March 17, 2025 – HepQuant, LLC continues to expand clinical availability of…
Events
March 18, 2025 - March 21, 2025Los Angeles, CA
Global Hepatitis Summit 2025
HepQuant’s Dr. Joanne Imperial, Chief Medical Officer, will be attending the Global Hepatitis Summit 2025 in Los Angeles and presenting a poster titled HepQuant DuO™ for Quantifying Liver Function and Physiology in the Clinic: Diagnostic Performance for Esophageal Varices in Patients with Treated and Active Chronic Hepatitis C, poster P-187.
March 21, 2025 - March 23, 2025San Antonio, TX
5th Annual Liver Connect Conference
HepQuant will participate in the 5th Annual Liver Connect Conference in San Antonio, TX. A silver sponsor of the event, the HepQuant team may be found at booth 17 in the exhibit hall. Three posters submitted by HepQuant will be featured during the conference. Poster 47: Initial Clinical Experience with…
November 15, 2024 - November 19, 2024San Diego, CA
AASLD, The Liver Meeting
HepQuant is excited that six abstracts, will be presented, three of which were deemed a Poster of Distinction, at The Liver Meeting 2024 on 11/16/24 and 11/17/24 linked below. Poster of Distinction: The Oral Cholate Challenge Test Defines Likelihood of Large Esophageal Varices in an Overweight and Obese US Population …